Original research
par
Morford, Kenneth L. et al
Date de publication
2022
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.
Constatations/points à retenir
Benzodiazepine exposure at intake was not observed to impact 12-month treatment retention or duration. These findings support U.S. Food and Drug Administration (FDA) recommendations to not withhold medications for opioid use disorder from patients taking benzodiazepines.
La conception ou méthodologie de recherche
Retrospective cohort study of 2968 patients
Mots clés
Substitution/OAT
Clinical guidance
